Four Biotech Companies Pushing Boundaries in Cancer Treatment Innovation

The oncology sector is experiencing a transformative period, with innovative companies developing targeted therapies that offer new hope for patients battling challenging cancers. Four companies—OS Therapies, Candel Therapeutics, Y-mAbs Therapeutics, and Day One Biopharmaceuticals—are at the forefront of this medical innovation.

OS Therapies is making significant strides in treating osteosarcoma, a rare bone cancer primarily affecting children and young adults. Their lead drug, OST-HER2, showed a statistically significant improvement in 12-month event-free survival during clinical trials. The company aims to submit a Biologics License Application to the FDA by late 2025, potentially receiving Accelerated Approval by year-end.

Candel Therapeutics is developing immunotherapies targeting various cancers, including pancreatic and prostate cancer. Their clinical trials have demonstrated promising results, with patients receiving CAN-2409 experiencing substantially improved median overall survival compared to control groups. The company has received multiple FDA designations that could expedite drug development.

Y-mAbs Therapeutics is focused on pediatric cancer, particularly neuroblastoma, with DANYELZA—the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Their clinical trials have shown a 50% overall response rate, offering hope for children with limited treatment options.

Day One Biopharmaceuticals is addressing pediatric low-grade glioma with OJEMDA, a targeted therapy approved under accelerated approval. The drug has already generated significant interest, with over 1,600 prescriptions written in its first eight months and net product revenues of $57.2 million in 2024.

These companies represent a critical advancement in oncology, targeting rare and complex cancers where traditional treatments have shown limited success. Their innovative approaches—including immunotherapies, targeted treatments, and novel drug platforms—demonstrate the potential to transform cancer care, particularly for pediatric patients.